MannKind

MannKind Long-term Debt

The Long-Term Debt of MannKind (MNKD) as of Nov 17, 2026 is 318.36 M USD. In the previous year, Long-Term Debt was 36.05 M USD — a change of 783.09% (higher).

Long-term Debt

318.36 MUSD

YoY

783.09%

Last updated:

Long-Term Debt of MannKind is 2025 318.36 M USD. Long-Term Debt of MannKind was 2024 36.05 M USD. It decreases by 783.09% higher compared to the previous year.

The MannKind Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
19.10 M USD
Jan 1, 2019
5.00 M USD
Jan 1, 2020
5.00 M USD
Jan 1, 2021
223.94 M USD
Jan 1, 2022
225.40 M USD
Jan 1, 2023
248.70 M USD
Jan 1, 2024
36.05 M USD
Jan 1, 2025
318.36 M USD
The MannKind Long-term Debt history
YEARLong-term DebtYoY
318.36 MUSD+783.09%
36.05 MUSD-85.50%
248.70 MUSD+10.34%
225.40 MUSD+0.65%
223.94 MUSD+4,378.88%
5.00 MUSD0.00%
5.00 MUSD-73.82%
19.10 MUSD-21.76%
24.41 MUSD-11.67%
27.64 MUSD+0.08%
27.61 MUSD-44.24%
49.52 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MannKind Stock analysis

What does MannKind do? MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MannKind stock

Long-Term Debt of MannKind is 318.36 M USD in 2025.

Long-Term Debt of MannKind changed from 36.05 M USD to 318.36 M USD, representing a 783.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt MannKind since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's MannKind historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MannKind

All Key Metrics — MannKind